Amy Hallman Rice

Cooley advised AttackIQ, a leading vendor of adversarial exposure validation solutions, on its acquisition of assets from DeepSurface Security, a security posture management and vulnerability prioritization company. Partner Matt Browne led the Cooley team advising AttackIQ.

Cooley advised Cortica, a leading provider of advanced neurological therapies for children with autism and other developmental differences, on its $80 million financing round, co-led by Morgan Health and Nexus NeuroTech Ventures.

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.

Cooley advised MannKind, a company focusing on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases, on the sale of a 1% royalty in net sales of Tyvaso DPI (treprostinil) inhalation powder to Sagard Healthcare for up to $200 million.

Cooley advised CinCor Pharma, a clinical-stage biopharmaceutical company, on its definitive agreement to be acquired by AstraZeneca. M&A partners Rama Padmanabhan and Rowook Park and corporate partners Div Gupta and Sarah Sellers led the Cooley team.